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ABSTRACT 
 
Background It remains uncertain whether patients with atrial fibrillation (AF) and a single 
additional stroke risk factor (CHA2DS2-VASc score = 1 in males, 2 in females) should be 
treated with oral anticoagulation (OAC). We investigated the risk of ischemic stroke, systemic 
embolism and death in a community-based cohort of unselected AF patients with a 0-1 stroke 
risk factors, based on the CHA2DS2-VASc score. 
Methods Among 8962 patients with AF seen between 2000 and 2010, 2177 (24%) had 0 or 1 
additional stroke risk factor, of which 53% were prescribed OAC.  
Results Over a follow-up of 979±1158 days, 151 (7%) had a major adverse event 
(stroke/systemic thromboembolism/death). Prescription of OAC was not associated with a 
better prognosis for stroke/systemic thromboembolism/death for ‘low risk’ patients (ie. 
CHA2DS2-VASc score = 0 for men or 1 for women) [adjusted Hazard Ratio(HR) 0.68, 95% 
CI 0.35-1.31, p=0.25 ]. OAC use was independently associated with a better prognosis in AF 
patients with a single additional stroke risk factor (ie. CHA2DS2-VASc score = 1 in males, 2 
in females) [adjusted HR 0.59, 95% CI 0.40-0.86, p=0.007].  
Conclusion Among AF patients with one single additional stroke risk factor (CHA2DS2-
VASc score = 1 in males, 2 in females), OAC use was associated with an improved prognosis 
for stroke/systemic thromboembolism/death.  
  
Keywords: Atrial fibrillation; oral anticoagulant; CHA2DS2-VASc score 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
INTRODUCTION  
Atrial fibrillation (AF) is the most common arrhythmia, and confers a substantial risk of fatal 
and disabling stroke. Randomized trials for patients with AF have conclusively demonstrated 
that compared to placebo, oral anticoagulation (OAC) reduces the risk of stroke/systemic 
embolism by 64% and all cause mortality by 26% 1. 
Despite the five-fold excess risk of stroke with AF, this risk is not homogeneous and depends 
on the presence of various risk factors. These risk factors have been used to formulate various 
stroke risk stratification schemes. Current European and the ACC/AHA/HRS guidelines 
recommend use of the CHA2DS2VASc score, but the approach is different in different 
guidelines 2–4.  
The 2014 AHA/ACC/HRS guidelines recommend a categorical approach to stroke risk 
assessment, and treatment decisions based on whether patients are low, moderate or high risk. 
For those with a CHA2DS2VASc score ≥2, OAC is recommended, whilst for those with a 
CHA2DS2VASc score 0, no antithrombotic therapy is recommended. However, for those with 
a CHA2DS2VASc score 1, the recommendation is for ‘no antithrombotic therapy, aspirin or 
OAC’ (Class IIb, level of evidence C) 4. In contrast, the ESC and NICE guidelines 
recommend the initial step is to identify ‘low risk’ patients (ie. CHA2DS2VASc score 0 for 
males, 1 for females) who do not need any antithrombotic therapy. The subsequent step is to 
offer effective stroke prevention (ie. OAC) to patients with ≥1 stroke risk factors 3,5. 
The aim of this study was to study the impact of OAC use on stroke/systemic embolism/death 
in patients with AF and one single additional stroke risk factor (that is, CHA2DS2-VASc score 
= 1 in males, 2 in females), compared with that of low risk patients (CHA2DS2-VASc score = 
0, or 1 in females), Second, we investigated the relative contribution to stroke/systemic 
embolism/death or the various risk factor components of the CHA2DS2-VASc score.  
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METHODS  
Study population 
The detailed methods and design of the Loire Valley AF Project has previously been reported 
6–8
. We included all patients seen in the cardiology department at the University Hospital of 
Tours between January 2000 and December 2010 with a diagnosis of AF, and identified 
patients who were categorised as low risk (CHA2DS2-VASc score = 0, or 1 in females) and 
those with one single additional stroke risk factor (ie. CHA2DS2-VASc score = 1 in males, 2 
in females).  
AF (paroxysmal, persistent or permanent) was defined on the electrocardiogram by the 
replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in 
amplitude, shape, and timing, associated with an irregular, frequently rapid ventricular 
response when atrioventricular conduction was intact. Treatment at discharge was obtained by 
the screening of hospitalization reports. Patients were excluded from the study if their 
antithrombotic treatment at discharge was unknown. We also excluded from the analysis 
patients with a known mitral stenosis or any valvular prosthesis in whom OAC was 
theoretically indicated. Characteristics of the patients were obtained by the coding system 
filled in for each patient hospitalized through the computerized system of the institution, 
based on the international classification of diseases (ICD-10) (supplementary table 1). With 
these characteristics, the CHA2DS2-VASc score could be calculated retrospectively as 
previously described 2: 2 points assigned for a history of stroke/transient ischemic 
attack/thromboembolism and age ≥ 75 years; 1 point assigned for age 65-74 years, history of 
hypertension, diabetes, recent cardiac failure, vascular disease (myocardial infarction, 
complex aortic plaque, and peripheral arterial disease), and female gender.  
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During the follow-up of the patients, deaths from all causes and strokes were recorded 
whenever they occurred in our institution, which includes a total of 4 hospitals covering all 
medical and surgical specialties. Our hospital covers an area of 4000 km2, and a population of 
400.000 inhabitants and is the only public institution in the area. In addition, mortality data 
were obtained using a search tool from the website of the main regional newspaper of the 
Région Centre, ‘La Nouvelle République’ 
(http://nrco.lanouvellerepublique.fr/dossiers/necro/index.php).  
In this ‘real world’ registry, some deaths could be due to undiagnosed stroke, as cerebral 
imaging or post mortems were not mandated, unlike a clinical trial. Also, OAC use reduces 
the risk of stroke/systemic embolism and all-cause mortality. Thus, the primary adverse 
endpoint for this study was the composite of ‘stroke/systemic embolism/death’. Severe 
bleeding was defined as a decrease in the blood haemoglobin level of more than 5.0 g/dL 
(including the period around the coronary interventional procedure), the need for transfusion 
of one or more unit of blood, the need for corrective surgery, the occurrence of an intracranial 
or retroperitoneal haemorrhage, or any combination of these events. A secondary adverse 
endpoint for this study was the composite of ‘stroke/systemic embolism/death and major 
bleeding’. 
 
Statistical analysis  
Patient characteristics are reported as percentages and the mean ± standard deviation (SD). 
Comparisons between groups were made using chi-square tests for comparing categorical 
variables and the Student t test or non-parametric Kruskal Wallis test were appropriate for 
continuous variables. In order to identify independent characteristics associated with the 
occurrence of an event (stroke or death) during the follow-up, a multivariate analysis was 
performed and potential confounders were entered into a Cox model for adjustment. A 
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Kaplan-Meier survival analysis with the log-rank test was carried out. A Cox proportional 
hazards regression model was used to calculate the hazard ratio (HR) of some predictive 
factors and their 95% confidence interval (CI) for the incidence of death/stroke or systemic 
thromboembolism. The proportional hazard assumption was checked by plotting the log-log 
Kaplan Meier curves. A p-value < 0.05 was considered statistically significant. Statistical 
analysis was carried out with the Statview 5.0 software (Abacus Concepts, Berkley, CA, 
USA).  
 
Ethics approval 
The study was approved by the institutional review board of the Pole Coeur Thorax Vaisseaux 
from the Trousseau University Hospital (Tours, France) on December 7, 2010 and registered 
as a clinical audit. Ethical review was therefore not required. Patient consent was not sought. 
Patient data were utilized only to facilitate the cross referencing of data sources and records 
were otherwise anonymous. The study was conducted retrospectively, patients were not 
involved in its conduct, and there was no impact on their care. 
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RESULTS  
From 8962 unselected and consecutive patients with AF seen between 2000 and 2010, there 
were 2177 (24%) with 0 or 1 single additional stroke risk factors (CHA2DS2-VASc score = 0 
or 1 in males, 1 or 2 in females). Mean age was 55±14 and 662 (30%) were female. Figure 1 
shows repartition of the risk factors and the percentage of OAC use for the different criteria in 
the study population. OAC use was lower for patients with no additional risk factor 
(CHA2DS2-VASc score = 0, or 1 in females) and those with a history of vascular disease, and 
higher for those with a history of heart failure, hypertension, diabetes and those age ≥65 
years. Baseline characteristics of the patients with AF and 0 or 1 single additional stroke risk 
factor are shown in Table 1. Patients treated with OAC were older and more likely to be male 
and more frequently had heart failure, hypertension, valvular disease, a history of chronic 
pulmonary disease, permanent AF and an implantable device. During follow-up, patients with 
no OAC were more often treated with an antiplatelet agent (44% vs. 7%, p<0.0001) whereas 
those with an OAC were more often treated using ACE inhibitors or angiotensin 2-blockers, 
beta-blockers and diuretics.  
 
During a follow-up of 979±1158 days, 151 events of the primary endpoint (death, stroke or 
systemic thromboembolism) were recorded in AF patients with 0 or 1 single additional risk 
factor. In addition, 30 patients had a major bleeding and 163 patients had events of the 
secondary endpoint. Figure 2 shows the population sorted in 6 groups (5 components of the 
score, except female gender, and CHA2DS2-VASc score of 0). Low risk patients (CHA2DS2-
VASc score =0, or 1 in females) had the lowest event rate compared to other groups 
(p<0.0001). No significant differences were found between the 5 other groups (p=0.34). The 
comparison for the occurrence of stroke/systemic embolism/death in AF patients with 0 or 1 
single additional risk factor (CHA2DS2-VASc score = 0 or 1 in males, 1 or 2 in females) 
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according to gender and shows no significant difference between females and males (p=0.15), 
even after adjustment for age (HR = 0.72, p=0.08) (figure2) .  
 
When comparing the occurrence of stroke/systemic embolism/death’ in patients with no 
additional stroke risk factor (ie. CHA2DS2-VASc score = 0, or 1 in females) treated with 
OAC vs those treated with no OAC there was no advantage with OAC use (p=0.67), even 
after adjustment for age and gender (HR=0.68, p=0.25) (figure 3). In patients with one single 
additional risk factor (ie. CHA2DS2-VASc score =1 in males, 2 in females), patients treated 
with OAC had a lower risk of stroke/systemic embolism/death (p=0.01), and the lower risk 
persisted even after adjustment on age and gender (HR= 0.59, p=0.007) (Figure 3).  
 
Figure 4 illustrates the rate of events in AF patients with a CHA2DS2-VASc score of 1 (male 
with 1 additional risk factor or female with 0 additional risk factor) treated with OAC 
according to ESC guidelines (no OAC for female, OAC for male) versus patients treated in a 
different way. Patients treated with OAC as proposed by the ESC guidelines had a lower rate 
of events of the primary and of the secondary endpoints and the results were still significant 
after adjustment for age and gender.  
 
The different presumed risk factors for stroke/systemic embolism/death were analysed by 
univariate and multivariate analysis (Table 2). Older age, heart failure, chronic pulmonary 
disease, kidney disease and the lack of OAC treatment were independently associated with a 
higher risk of events. OAC use was independently associated with a 45% decrease in the 
occurrence of events. Table 3 indicates the hazards ratios for stroke/systemic embolism/death 
in patients with AF with 1 single additional stroke risk factor. Compared to patients with no 
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risk factor, hazard ratio of events with one single additional risk factor ranged from 1.48 for 
hypertension to 3.04 for heart failure and was statistically significant for patients with heart 
failure and those age ≥65 years.  
As a sensitivity analysis, our results were similar even when use of beta-blocker and/or ACE 
inhibitor was added in the multivariable Cox models for the endpoints presented in table 2 
(death, stroke or systemic TE) and table 5 (death, stroke/TE or major bleeding) [full data not 
shown]. 
 
 
DISCUSSION  
In this cohort study, our principal finding was that among AF patients with one single 
additional stroke risk factor (CHA2DS2-VASc score = 1 in males, 2 in females), OAC use was 
associated with an improved prognosis for stroke/systemic thromboembolism/death. Oral 
anticoagulation was not associated with a better prognosis in patients in the ‘low risk’ 
category (CHA2DS2-VASc score = 0, or 1 in females). Overall, this supports the strategy for 
OAC proposed in the current European and NICE guidelines. Adding major bleeding in the 
combined endpoint of our analysis led to similar findings. 
 
Our data are consistent with a recent Danish registry analysis and the Taiwanese national 
insurance study, where AF patients with a single risk factor had an ischaemic stroke risk of 
>1.5%/year and >2.5%/year, respectively 9,10. In contrast, one recent study from Sweden 
suggested that the previous estimate of the risk of ischemic stroke in AF patients with one risk 
factor may be <1% but this study excluded any patient started on OAC during follow-up, thus 
‘conditioning for the future’ since higher risk subjects would have been excluded 11.  
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As with Chao et al. 12, which was a study conducted in an Asian/non-European patient 
population, the present study shows that the effects of factors which contribute to a 
CHA2DS2-VASc score of 1 did not vary significantly. However, in an initial validation cohort 
for the CHA2DS2-VASc score in Denmark, the relative risk of ischemic stroke associated with 
the 6 risk factors leading to a CHA2DS2-VASc score of 1 varied significantly and was up to 5 
times greater between the highest (diabetes) and lowest risk (vascular disease) 9. Huang et al. 
13
 found that among the risk factors, hypertension created the highest risk, followed by age 
and female gender, and there was no statistically significant increase in ischemic strokes 
among AF patients with a history of heart failure, diabetes or vascular disease other than 
strokes. By contrast, Healey et al. did not find that a history of hypertension was an 
independent high risk factor of stroke in the ACTIVE-W trial 14. The influence of 
hypertension on prognosis may have changed over recent years due to a more efficient 
management of hypertension in patients and better blood pressure control15. Vascular disease 
has also been determined as an independent risk factor of stroke in AF patients 16. This was 
particularly apparent especially when Asian individuals were compared to Europeans 17.  
 
Our analysis where female and male patients were considered together may suffer from a lack 
of power for some subgroups. Overall, we did not find significant differences in relative 
hazard between each criteria of the score (gender excepted) in our series of unselected and 
well characterized AF patients, and we suggest that patients with one additional stroke risk 
factor have a relatively homogeneous increased risk, although a history of heart failure may 
be more impacted. Of note, all point estimates were >1.0 (ranging from 1.48 to 3.04) but 
small sample size led to some confidence intervals crossing neutral.  
 
Female gender has been consistently demonstrated to be an independent risk factor for 
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ischemic stroke among patients with AF18-20. In the 2012 focused update of the ESC 
guidelines for management of AF, the recommendation is that female AF patients aged <65 
and without any additional risk factor are at a low risk of ischemic stroke and should not be 
prescribed antithrombotic therapy. In our study, we cannot conclude that female AF patients 
with a CHA2DS2-VASc of 1 have a higher risk of ischemic stroke than their male counterparts 
as found by Huang et al. As the mean age of our patients with CHA2DS2-VASc score of 1 was 
61 years, many would be >65 years after 40 months of follow-up. Any increase in the risk of 
ischemic stroke at this time would likely also be related to increasing age, not female gender 
alone, consistent with the suggestion that female gender would be a stroke risk modifier rather 
than a risk factor per se.  
 
In our study, there was no benefit for OAC in reducing the occurrences of stroke/systemic 
thromboembolism/death in AF patients with no additional stroke risk factor (CHA2DS2-VASc 
score = 0, or 1 in females). By contrast, OAC treatment was associated with a clear benefit 
when compared with no OAC treated patients when one additional stroke risk factor was 
present (CHA2DS2-VASc score = 1 in males, 2 in females). Chao et al.12 support 
recommending OAC for all AF patients except those at a very low stroke risk (as identified by 
a CHA2DS2-VASc score of 0 or 1 for women) and our findings corroborate these conclusions 
and the 2012 ESC guidelines. In contrast, the ACC/AHA/HRS guidelines recommend no 
antithrombotic therapy or treatment with either OAC or aspirin for CHA2DS2-VASc score=1, 
in other words: “do what you like", but our findings do not support this strategy. The trials 
with non-vitamin K antagonist oral anticoagulant agents (NOACs) also provide data for 
benefit even with a single risk factor albeit with using the CHADS2 score. Thus, physicians 
should appreciate that even a single risk factor confers real risks of stroke/systemic 
thromboembolism/death, and OAC would reduce this overall risk.  
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Limitations  
The main limitation of this study is in its observational nature. Although it was adjusted for 
several variables, some patients might have higher acuity of illness and it is still possible that 
residual confounding factors between the groups could have been omitted in the analysis. The 
distribution of medications differed between groups, and the observational method, even after 
multivariate adjustment, raises a question as to whether some groups were merely managed 
better with a possible treatment bias, particularly those with OAC use. However, the inclusion 
criteria noticeably made the population relatively homogeneous. Due to the hospital based 
nature of the cohort, the absolute risk of death or stroke was higher than that of previous 
population-based series18-20. This may be because such patients tend to be sicker than those in 
a community-based cohort. While we carefully ascertained all strokes and intracranial 
haemorrhage through examination and hospitalization records, laboratory and imaging results, 
patients with a milder form of stroke and/or intracranial haemorrhage who were not 
hospitalized may have not been seen in hospital. Studies with a long-term follow-up as this 
one are often at risk of changes in treatment during the follow-up, which is impossible to 
make adjustments for in the multivariable analysis. Quality of anticoagulation with time in 
therapeutic range was not available. Another caveat is that we did not have access to data on 
strokes occurring outside of our area. If a resident moved from the area and had stroke 
diagnosed elsewhere, information on the event was unavailable to us.  
However, we rather see the ability to report nonrandomized, real-world registry data from a 
large cohort of consecutive patients recruited as an advantage, not a weakness, in that the data 
are complementary (and supportive) to the data reported in randomized, clinical trials. In fact, 
a large randomized control trial addressing the issues presented here will probably not be 
performed soon. Observational studies such as ours may be of value because they shed light 
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on the use of competing treatment options in current practices and because they include 
patients with a higher risk profile who are frequently not represented in clinical trials. 
 
 
 
 
CONCLUSION  
In a real life cohort study, among AF patients with one single additional stroke risk 
factor (CHA2DS2-VASc score = 1 in males, 2 in females), OAC use was associated with an 
improved prognosis for stroke/systemic thromboembolism/death.  
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LEGENDS TO FIGURES  
 
Figure 1. Flow chart of patients with non valvular AF and low risk of stroke (CHA2DS2-VASc score 
0, or 1 in females) or with 1 additional risk factor (CHA2DS2-VASc score 1 in males, 2 in females) 
  
Figure 2.  
Top panel : Comparison of occurrence of primary endpoint (death, stroke or systemic 
thromboembolism) in AF patients with low risk of stroke (CHA2DS2-VASc score 0, or 1 in females) 
or with 1 additional risk factor (CHA2DS2-VASc score 1 in males, 2 in females)   
Lower panel: Comparison of occurrence of primary endpoint (death, stroke or systemic 
thromboembolism) in AF patients with low risk of stroke (CHA2DS2-VASc score 0, or 1 in females) 
or with 1 additional risk factor (CHA2DS2-VASc score 1 in males, 2 in females) according to male or 
female gender  
 
Figure 3.  
Top panel: Comparison of occurrence of primary endpoint (death, stroke or systemic 
thromboembolism) in AF patients with low risk of stroke (CHA2DS2-VASc score 0, or 1 in females) 
according to therapy with OAC or no OAC  
Lower panel: Comparison of occurrence of primary endpoint (death, stroke or systemic 
thromboembolism) in AF patients with 1 additional risk factor (CHA2DS2-VASc score 1 in males, 2 in 
females) according to therapy with OAC or no OAC  
 
Figure 4. Comparison of occurrence of primary endpoint (death, stroke or systemic 
thromboembolism, top panel) or secondary endpoint (death, stroke, systemic thromboembolism or 
major bleeding, lower panel) in AF patients with CHA2DS2-VASc score 1 (male with 1 additional risk 
factor or female with 0 additional risk factor) treated in accordance with OAC according to ESC 
guidelines versus others patients  
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TABLE 1. BASELINE CHARACTERISTICS OF THE POPULATION OF AF PATIENTS WITH LOW RISK OF STROKE 
(CHA2DS2-VASC SCORE 0, OR 1 IN FEMALES) OR WITH 1 ADDITIONAL RISK FACTOR (CHA2DS2-VASC SCORE 1 IN 
MALES, 2 IN FEMALES) ACCORDING TO THERAPY WITH OAC OR NO OAC 
 
 Patients treated 
with no oral 
anticoagulant 
(n=956) 
Patient treated  
with oral 
anticoagulant 
(n=1053) 
 
p 
Age (years) (mean±SD) 50±15 58±11 <0.0001 
Male gender 615 (64%) 786 (77%) <0.0001 
Permanent atrial fibrillation 126 (13%)  425 (40%) <0.0001 
Heart Failure 120 (13%) 213 (20%) <0.0001 
Hypertension 42 (4%) 75 (7%) 0.009 
Diabetes mellitus 14 (1%) 21 (2%) 0.36 
Vascular diseases 30 (3%) 23 (2%) 0.18 
Coronary artery disease 92 (10%) 109 (10%) 0.59 
Previous myocardial infarction 22 (2%) 16 (2%) 0.19 
Previous CABG 9 (1%) 15 (1%) 0.32 
Previous PCI 39 (4%) 27 (3%) 0.06 
Valvular disease 65 (7%) 112 (11%) 0.002 
Thyroid disorder 51 (5%) 57 (5%) 0.94 
Alcohol abuse 37 (4%) 45 (4%) 0.65 
Renal insufficiency 13 (1%) 13 (1%) 0.80 
Pacemaker or ICD 65 (7%) 117 (11%) 0.0008 
Chronic pulmonary disease 43 (4%) 77 (7%) 0.008 
Medication during follow-up 
Antiplatelet agent 416 (44%) 73 (7%) <0.0001 
Angiotensin converting enzyme inhibitor 
or Angiotensin 2-blocker 
102 (11%) 286 (28%) <0.0001 
Beta blocker 330 (35%) 477 (46%) <0.0001 
Diuretic 72 (8%) 175 (20%) <0.0001 
 
CABG = coronary artery bypass grafting, ICD = implantable cardioverter defibrillator, PCI = 
percutaneous coronary intervention 
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TABLE 2.UNIVARIATE AND MULTIVARIATE ANALYSIS OF PRIMARY ENDPOINT (DEATH, STROKE OR SYSTEMIC 
THROMBOEMBOLISM) PREDICTORS IN THE POPULATION OF AF PATIENTS WITH LOW RISK OF STROKE (CHA2DS2-
VASC SCORE 0, OR 1 IN FEMALES) OR WITH 1 ADDITIONAL RISK FACTOR (CHA2DS2-VASC SCORE 1 IN MALES, 2 IN 
FEMALES)  
 Univariate analysis Multivariate analysis 
 Hazard Ratio (95% 
Confidence Interval)  
p Hazard Ratio (95% 
Confidence Interval) 
p 
Age 1.05 (1.03-1.06) <0.0001 1.06 (1.04-1.08) <0.0001 
Female gender 0.77 (0.53-1.11) 0.16 0.72 (0.48-1.08) 0.12 
Heart Failure 2.04 (1.45-2.86) <0.0001 2.99 (1.95-4.57) <0.0001 
Hypertension 0.81 (0.41-1.59) 0.55 1.40 (0.66-2.95) 0.38 
Diabetes 1.25 (0.40-3.85) 0.71 2.75 (0.85-8.93) 0.09 
Vascular disease 1.18 (0.55-2.50) 0.67 1.36 (0.55-3.33) 0.50 
Coronary artery disease 1.45 (0.93-2.27) 0.10 1.22 (0.71-2.10) 0.48 
Valvular disease 2.04 (1.37-3.03) 0.0004 1.56 (1.01-2.41) 0.05 
Renal insufficiency 5.26 (2.63-10.0) <0.0001 4.55 (2.16-9.52) <0.0001 
Chronic pulmonary disease 2.04 (1.23-3.33) 0.01 1.94 (1.15-3.28) 0.01 
Permanent atrial fibrillation 1.10 (0.78-1.54) 0.60 0.94 (0.65-1.36) 0.73 
Oral anticoagulant treatment 0.83 (0.60-1.15) 0.25 0.55 (0.38-0.80) 0.002 
Antiplatelet treatment 1.03 (0.70-1.52) 0.88 0.80 (0.52-1.23) 0.31 
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TABLE 3 .HAZARD RATIO FORPRIMARY ENDPOINT (DEATH, STROKE OR SYSTEMIC THROMBOEMBOLISM) 
PREDICTORS IN PATIENTS WITH ATRIAL FIBRILLATION WITH 1 ADDITIONAL RISK FACTOR (CHA2DS2-VASC SCORE 
1 IN MALES, 2 IN FEMALES) COMPARED TO THE POPULATION OF AF PATIENTS WITH LOW RISK OF STROKE 
(CHA2DS2-VASC SCORE 0, OR 1 IN FEMALES) 
 
 Hazard Ratio (95% 
Confidence Interval)  
p 
 
Patients with no risk factor as 
reference 
 
No risk factor (n=1078) 1 - 
Heart Failure (n=377) 3.04 (1.99-4.63) <0.0001 
Hypertension (n=136) 1.48 (0.72-3.07) 0.29 
Age 65-74 (n=484) 2.40 (1.56-3.69) <0.0001 
Diabetes (n=41) 2.23 (0.69-7.24) 0.18 
Vascular disease (n=61) 2.11 (0.94-4.71) 0.07 
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TABLE 5.UNIVARIATE AND MULTIVARIATE ANALYSIS OF SECONDARY ENDPOINT (DEATH, STROKE , SYSTEMIC 
THROMBOEMBOLISM OR MAJOR BLEEDING) PREDICTORS IN THE POPULATION OF AF PATIENTS WITH LOW RISK OF 
STROKE (CHA2DS2-VASC SCORE 0, OR 1 IN FEMALES) OR WITH 1 ADDITIONAL RISK FACTOR (CHA2DS2-VASC 
SCORE 1 IN MALES, 2 IN FEMALES)  
 Univariate analysis Multivariate analysis 
 Hazard Ratio (95% 
Confidence Interval)  
p Hazard Ratio (95% 
Confidence Interval) 
p 
Age 1.03 (1.02-1.04) <0.0001 1.04 (1.03-1.06) <0.0001 
Female gender 0.81 (0.60-1.10) 0.17 0.75 (0.53-1.05) 0.09 
Heart Failure 1.93 (1.45-2.57) <0.0001 2.70 (1.90-3.85) <0.0001 
Hypertension 1.11 (0.67-1.82) 0.68 1.64 (0.93-2.87) 0.08 
Diabetes 1.14 (0.42-3.08) 0.79 2.38 (0.86-6.54) 0.09 
Vascular disease 1.19 (0.63-2.24) 0.59 1.38 (0.62-3.05) 0.43 
Coronary artery disease 1.46 (1.01-2.11) 0.05 1.48 (0.92-2.36) 0.11 
Valvular disease 5.41 (3.01-9.62) <0.0001 1.65 (1.14-2.39) 0.01 
Renal insufficiency 1.72 (1.10-2.70) 0.02 4.93 (2.45-9.90) <0.0001 
Chronic pulmonary disease 1.06 (0.80-1.41) 0.69 1.57 (0.99-2.50) 0.06 
Permanent atrial fibrillation 1.01 (0.76-1.32) 0.97 0.84 (0.62-1.15) 0.28 
Oral anticoagulant treatment 0.88 (0.63-1.23) 0.45 0.67 (0.49-0.92) 0.01 
Antiplatelet treatment 1.03 (1.02-1.04) <0.0001 0.81 (0.56-1.18) 0.27 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Online Supplement
e-Table 1. International Classification of Disease 10 (ICD-10) codes 
 
Comorbidity or medical history  Existing diagnoses between 1 January 2007 and 31 December 2011 
AF management care  I48  
AF symptoms  
Tachycardia  R000  
Chest pain  R072, R073, R074  
Palpitations  R002  
Strokes  
Ischaemic stroke  I63, I66, I67  
Stroke, unspecified  I64  
Haemorrhagic stroke  I60–I62, I69  
Transient ischaemic attack G45  
Systemic embolism  I74.2–I74.9  
Haemorrhages  
Intracranial bleeding  S064–S066  
Gastric/duodenal ulcer  K25–K28 (subcodes 0–2 and 4–6 only)  
Any severe bleeding  I850, I983, K625, K922  
Ischaemic heart disease  I20–I25  
Heart failure  I50, I110, I130, I132, I131, I139  
Including dyspnoea  R060  
Cardiac dysrhythmia  I47, I490–I493  
Abnormal cardiac conduction  I44, I45, I494, I495, Z450, Z950  
Valvular disease  I05–I091, I33–I39, Q22, Q23  
Hypertension  I10–I15  
Diabetes mellitus  E10–E14  
Vascular diseases  
Myocardial infarction  I21, I252  
Peripheral arterial disease  I70–I73  
Occlusions  I65, I77  
Obesity  E65–E66  
Abnormal renal function  N17–N19 (+N28) codes for renal insufficiency, transplantation (Z940, 
T861) and dialysis (Z49, Z992), E102, I12, I13  
Liver disease  K70–K77, procedures for liver transplantation or resection 
Dyslipidaemia  E78  
Thyroid disease  E00–E07  
Anaemia  D50–D64  
Platelet or coagulation defect  D65–D69  
Lung disease  J40–J70, J961  
Including emphysema and 
chronic obstructive pulmonary 
disease  
J43, J44  
Alcohol-related diagnoses  E244, F10, G312, G621, G721, I426, K292, K70, K860, O354, P043, 
Q860, T51, Y90, Y91, Z502, Z714  
Dementia  F00–F03  
Accidental falls  W00–W19, R26  
Cancer  Entire C-series  
AF, atrial fibrillation. 
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